TOPIRAMATE AND PHENTERMINE

Course overview

PHENTERMINE AND EXTENDED-RELEASE (ER) TOPIRAMATE HAVE BEEN USED SEPARATELY IN A VARIETY OF WAYS. PHENTERMINE WAS FIRST INTRODUCED IN 1959 AS PART OF AN ANTI-OBESITY COMBINATION DRUG. TOPIRAMATE WAS RELEASED FOR COMMERCIAL USE IN 1996. PHENTERMINE ON ITS OWN HAS BEEN USED FOR SHORT-TERM TREATMENT OF OBESITY IN COMBINATION WITH EXERCISE AND CALORIC RESTRICTION. TOPIRAMATE ON ITS OWN HAS BEEN USED TO TREAT PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, LENNOX-GASTAUT SYNDROME, AND AS A PROPHYLACTIC TREATMENT OF MIGRAINE HEADACHES. THE UNITED STATES FOOD AND DRUG ADMINISTRATION APPROVED THE COMBINATION OF THESE 2 DRUGS IN 2012 TO TREAT OBESITY. THE DRUGS ARE TO BE USED IN COMBINATION WITH A REDUCED-CALORIE DIET AND EXERCISE PROGRAM IN INDIVIDUALS WITH AN INITIAL BODY MASS INDEX (BMI) OVER 30 KG/M2 OR IN THOSE WITH A BMI OF OVER 27 IN COMBINATION WITH AT LEAST ONE OBESITY-RELATED COMORBIDITY. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, IMPORTANT ADVERSE EFFECTS, CONTRAINDICATIONS, TOXICITY, AND MONITORING, OF TOPIRAMATE/PHENTERMINE SO PROVIDERS CAN DIRECT PATIENT THERAPY WHERE THEY ARE INDICATED AS PART OF THE INTERPROFESSIONAL TEAM.